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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) regulatory protein, Nef, is an
attractive vaccine target because it is involved in viral pathogenesis, is expressed early in the viral
life cycle and harbors many T and B cell epitopes. Several clinical trials include gene-based vaccines
encoding this protein. However, Nef has been shown to transform certain cell types in vitro. Based
on these findings we performed a long-term toxicity and immunogenicity study of Nef, encoded
either by Modified Vaccinia virus Ankara or by plasmid DNA. BALB/c mice were primed twice with
either DNA or MVA encoding Nef and received a homologous or heterologous boost ten months
later. In the meantime, the Nef-specific immune responses were monitored and at the time of
sacrifice an extensive toxicological evaluation was performed, where presence of tumors and other
pathological changes were assessed.
Results: The toxicological evaluation showed that immunization with MVAnef is safe and does not
cause cellular transformation or other toxicity in somatic organs.
Both DNAnef and MVAnef immunized animals developed potent Nef-specific cellular responses
that declined to undetectable levels over time, and could readily be boosted after almost one year.
This is of particular interest since it shows that plasmid DNA vaccine can also be used as a potent
late booster of primed immune responses. We observed qualitative differences between the T cell
responses induced by the two different vectors: DNA-encoded nef induced long-lasting CD8+ T
cell memory responses, whereas MVA-encoded nef induced CD4+ T cell memory responses. In
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terms of the humoral immune responses, we show that two injections of MVAnef induce significant
anti-Nef titers, while repeated injections of DNAnef do not. A single boost with MVAnef could
enhance the antibody response following DNAnef prime to the same level as that observed in
animals immunized repeatedly with MVAnef. We also demonstrate the possibility to boost HIV-1
Nef-specific immune responses using the MVAnef construct despite the presence of potent anti-
vector immunity.
Conclusion: This study shows that the nef gene vectored by MVA does not induce malignancies
or other adverse effects in mice. Further, we show that when the nef gene is delivered by plasmid
or by a viral vector, it elicits potent and long-lasting immune responses and that these responses
can be directed towards a CD4+ or a CD8+ T cell response depending on the choice of vector.
Background
In the challenging race for an HIV-1 vaccine, many
researchers are considering genetic vaccines, either based
on viral vectors or as naked DNA vaccines, due to their
ability to induce protective immune responses in animal
models [1]. Although both modalities induce potent cel-
lular and humoral responses in animals [2,3] there is a
need to improve the potency of these types of vaccine [4].
To improve and broaden immune responses against HIV-
1, combinations of viral genes encoding structural, enzy-
matic and regulatory proteins of HIV-1 have been used [5-
8]. The HIV-1 regulatory genes tat and nef are attractive as
vaccine components since both are immunogenic and
harbor several T and B cell epitopes. In addition, they are
expressed early in the viral life cycle and are relatively well
conserved. These features have led to several vaccine trials
using the regulatory proteins, trials in which the proteins
have been concluded immunogenic and safe in both
humans and animals [9-12]. However, the regulatory
genes of HIV-1 have been shown to influence cellular
functions and also to interact with several mechanisms of
the host immune response. Nef has been shown to be
important for viral replication, viral pathogenesis and
progression to AIDS in infected persons [13,14]. The pro-
tein exhibits many intricate actions for helping the virus
avoid the immune system, including a potent down-regu-
lation of surface markers such as MHC class I and CD4
molecules (reviewed in [15]). More recently, Nef was
shown to redistribute the co-stimulatory molecules CD80
and CD86 away from the cell surface of antigen present-
ing cells [16]. Furthermore, Nef is able to interact with the
SH3 domain of Hck, a tyrosine kinase of the Src family.
This interaction can lead to the transformation of fibrob-
lasts and neuronal cells in vitro [17-20]. In addition, exper-
iments using transgenic mice constitutively expressing nef
in cells of the kidney support the protein's contribution to
the development of HIV-1 associated nephropathy
(reviewed in [21]). However, little is known about the
long-term effects after immunization with Nef. Transgenic
mice are well-suited for studying the role of Nef during
HIV-1-infection, since the protein in these models is con-
tinuously expressed in the animals. They are, however,
inappropriate for studying the effects after genetic immu-
nization, in which the protein is expressed only tran-
siently. To assess the potential long-term toxicity
following nef-immunization in a model that allows for
full necropsy and extensive investigation of the major
organs, we immunized mice with a recombinant viral vec-
tor, MVA, encoding Nef. This construct has been evaluated
for safety and immunogenicity in a clinical phase I trial
[10]. We chose to use BALB/c mice for evaluation of the
long-term toxicity and tumorgenicity of the vaccine con-
struct, since this strain of mice is less prone to spontane-
ous tumor development than other inbred mice [22-24].
Thus, the relative stability of BALB/c mice might better
mimic the conditions in an outbred human population.
The normal life span of female BALB/c mice is approxi-
mately twenty-four months [25]. By evaluating the toxic-
ity of the nef-encoding MVA construct in this mouse strain
over one year, we believe we have a good model for assess-
ing possible long-term side effects induced by Nef-vacci-
nation.
In parallel with the long-term toxicology, we explored the
long-term immune responses elicited either by repeated
single modality immunization or by heterologous plas-
mid DNA prime MVA boost regimen.
Results
Toxicology and histopathology
We immunized BALB/c mice with two injections of either
DNAnef intramuscularly or MVAnef intraperitoneally.
Forty weeks later the animals received a homologous or
heterologous boost (see Figure 1 for immunization proto-
col). Three weeks after the late boost animals were sacri-
ficed and the mice immunized with MVAnef were
subjected to extensive toxicological investigations, per-
formed according to good laboratory practice (GLP).
Gross pathology
The immunization schedule included two injections at
weeks 0 and 5 and a boost at week 44 (Figure 1). Necropsy
was performed on animals at the time of sacrifice. No
macroscopic changes that could be attributed to the injec-Infectious Agents and Cancer 2007, 2:14 http://www.infectagentscancer.com/content/2/1/14
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tion of MVAnef were detected. There were no differences
in spleen weight between the groups of animals (data not
shown). During the course of the experiment, two ani-
mals immunized with MVAnef died (one in group A and
one in group B, see Figure 1 for immunization protocol
and number of animals/group). One died as a result of a
misplaced i.p. injection and the other from an unknown
cause. The latter animal could not be subjected to
necropsy due to post-mortem damage inflicted by the
cage mates.
Histopathology
Minor incidental changes were noted in some of the ana-
lyzed organs; they were considered to be related to the
background pathology seen in mice of this strain and age
(Table 1). Minimal to slight lymphoid cell accumulation
was noted in lungs of both MVA immunized animals and
control animals, possibly an effect of the inhalation of iso-
flurane prior to sacrifice. No malignancies were noted in
any of the animals. Two MVAnef injected animals had
increased extra-medullary hematopoiesis of the spleen. A
variation of lymphoid cell accumulation or minimal to
slight inflammation occurred without indications of any
malignancies or other serious pathological changes.
Hematology
The bone marrow of all animals displayed normal cellu-
larity (Table 2). Megakaryocytes were found in normal
Table 1: Individual microscopic findings
Group:Animal Lung Liver Spleen Lymph Node Kidney Ovaries
MVAx3:1 0 0 0 0 0 nd
MVAx3:2 Congestion 3 0 0 nd 0 0
MVAx3:3 0 0 0 nd 0 nd
MVAx3:4 0 0 0 0 0 0
MVAx3:5 0 MiFo inflammation 2 0 0 Unilateral Chro 
pyelonephritis 1
0
MVAx3:6 Lymphoid cell acc. 2 MiFo inflammation 1 0 0 0 0
MVAx3:7 Lymphoid cell acc. 2 0 0 0 0 0
MVAx3:8 0 Peri. inflammation 2 Incr. extramedullary 
hematopoiesis 2
nd 0 0
MVAx3:9 0 0 0 nd 0 Unilateral cyst
MVAx3:10 Lymphoid cell acc. 1 Peri. inflammation 1 Incr. extramedullary 
hematopoiesis 1 
Hemosiderosis 1
00n d
PBSx2+MVAx1:1 Lymphoid cell acc. 1 MiFo inflammation 1 0 nd 0 0
PBSx2+MVAx1:2 0 0 0 nd 0 nd
PBSx2+MVAx1:3 0 0 0 nd 0 0
PBSx2+MVAx1:4 0 0 0 0 0 0
PBSx3:1 0 MiFo inflammation 2 Lymphoid hyperplasia 1 0 0 0
PBSx3:2 Lymphoid cell acc. 1 0 0 nd 0 0
PBSx3:3 0 0 0 nd 0 0
PBSx3:4 0 0 0 nd 0 nd
PBSx3:5 0 0 0 0 0 0
PBSx3:6 0 0 0 0 0 0
Abbreviations: acc = accumulation, MiFo = Microfocal, Incr = Increased, Peri = Periportal, Chro = Chronic, nd = not done
Grading of changes: 0 = No changes, 1 = Minimal changes, 2 = Slight changes, 3 = moderate changes, 4 = Marked changes, 5 = Severe changes,
Experimental setup Figure 1
Experimental setup.
Week 5 04 4 4 7
Prime
Boost
Sacrifice
Group No. of mice Prime Boost
A 7 2xMVAnef MVAnef
B 7 2xMVAnef MVAwt
C 8 2xPBS MVAnef
D 7 2xPBS PBS
E 5 2xDNAnef MVAnef
F 5 2xDNAnef DNAnefInfectious Agents and Cancer 2007, 2:14 http://www.infectagentscancer.com/content/2/1/14
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numbers and were of normal size. Staining for iron was
positive in all bone marrow samples. The blood of all ani-
mals showed a moderate neutropenia, evaluated as a
slight decrease of segmented granulocytes, while lym-
phocytes as well as monocytes were found in normal
numbers. There were no immature cells in the peripheral
circulation and no pathological proliferation of blood
cells was noted. The red cells of animals in all groups,
both vaccinated and controls, showed a slight to moder-
ate degree of anisocytosis, poikilocytosis and polychro-
masia. No nucleated red cells could be found but many
cells contained a Howell-Jolly body. Platelets were found
in normal or slightly increased numbers. Despite the
occurrence of moderate neutropenia in all animals,
including the control animals that received intraperito-
neal injections of PBS, no animal showed any toxic effect
leading to a decreased cellularity of the bone marrow. The
findings in immunized animals could not be distin-
guished from non-immunized animals and were attrib-
uted to background histology of animals of this strain and
age.
Vaccine-induced HIV-1-specific immune responses
MVA boosts a DNA primed humoral Nef response
Animals primed with either DNAnef or MVAnef and sub-
sequently boosted with MVAnef (groups E and A, respec-
tively) displayed significantly stronger humoral responses
against Nef than animals in the other groups (Figure 2).
Interestingly, three injections of plasmid-encoded Nef did
not induce Nef-specific antibodies. However, a single
boost with MVAnef served to enhance the antibody
response following a DNA prime to the same levels as
after three injections with MVAnef.
DNA and MVA induce Nef-specific cellular responses
Cellular immune responses in peripheral blood were
assessed at three time points following the two initial
injections (Figure 3). Significant cellular responses to Nef
were detected two weeks after the second immunization.
Animals immunized with either DNAnef or MVAnef dis-
played a Nef-specific cellular response as measured by
IFN-γ production after stimulation of PBMC with overlap-
ping peptides representing the full Nef protein. This initial
response declined over time and was undetectable at 17
weeks after the second immunization.
Similar levels of cellular responses after MVA and DNA late boost 
immunization
After the late boost (at week 44, corresponding to 39
weeks after the second immunization, see Figure 1), the
most robust anti-Nef responses in splenocytes were seen
in animals primed with DNAnef and boosted either with
MVAnef (group E; DNAnef followed by MVAnef) or with
an additional injection of DNAnef (group F; DNAnef fol-
lowed by DNAnef) (Figure 4a). Animals in these two
groups responded with comparable levels of IFN-γ pro-
duction following stimulation of splenocytes with pep-
tides overlapping Nef. Furthermore, the levels of IFN-γ
Table 2: Individual hematopathology findings
Blood Smears Bone marrow
Group:Animal Segm Ly/Mo NRC A PC PCR HJB Plt Cellularity Megakaryocytes Iron contents
MVAx3:1 decr nr - ++ + ++ + nr 100% nr +
MVAx3:2 decr nr - + + + + nr 100% nr +
MVAx3:3 decr nr - + + + + nr 100% nr +
MVAx3:4 decr nr - + + ++ ++ nr 100% nr +
MVAx3:5 decr nr - + + + + incr 100% nr +
MVAx3:6 decr nr - + + + + nr 100% nr +
MVAx3:7 decr nr - (+) - - + incr 100% nr +
MVAx3:8 decr nr - + + + + nr 100% nr +
MVAx3:9 decr nr - + + + + nr 100% nr +
MVAx3:10 decr nr - + + + + nr 100% nr +
PBSx2+MVAx1:1 decr nr - + + + + nr 100% nr +
PBSx2+MVAx1:2 decr nr - + + + + incr 100% nr +
PBSx2+MVAx1:3 decr nr - + + + + nr 100% nr +
PBSx2+MVAx1:4 decr nr - + + + + incr 100% nr +
PBSx3:1 decr nr - + + + + incr 100% nr +
PBSx3:2 decr nr - + + + + incr 100% nr +
PBSx3:3 decr nr - + + + + incr 100% nr +
PBSx3:4 decr nr - - - (+) (+) incr 100% nr +
PBSx3:5 decr nr - - - (+) (+) incr 100% nr +
PBSx3:6 decr nr - - - (+) (+) incr 100% nr +
Abbreviations: Segm = Segmented granulocytes, Ly/Mo = Lymphocytes/monocytes, NRC = Nucleated red cells, A = Anisocytosis, PC = 
Poikilocytosis, PCR = Polychromasia, HJB = Howell Jolly Bodies, Plt = Platelets, nr = non remarkable, incr = increased, decr = decreasedInfectious Agents and Cancer 2007, 2:14 http://www.infectagentscancer.com/content/2/1/14
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responses by spleen cells displayed by these animals were
similar to those in the animals immunized three times
with MVAnef (group A; MVAnef followed by MVAnef).
Nef-specific responses in animals primed twice with
MVAnef and boosted with wild-type MVA (group B;
MVAnef followed by MVAwt) were weak. Here, a third
injection of MVAnef (group A) was needed to induce
detectable cellular immune responses to Nef (Figure 4a).
Injection of MVAnef once (group C; PBS followed by
MVAnef) did not result in measurable immune responses
(Figure 4a). Judging from IL-2 measurements (Figure 4b),
the strongest responses were found in animals primed
with DNAnef and boosted either with an additional injec-
tion of DNAnef (group F; DNAnef followed by DNAnef)
or with MVAnef (group E; DNAnef followed by MVAnef).
These results emphasize previous findings that plasmid
DNA followed by a viral vector boost might be superior to
a repeated immunization with the viral vector [26].
Importantly, we also show that DNA can be used as a late
boost of DNA primed immune responses.
Plasmid-encoded Nef induces CD8+ responses, whereas Nef 
encoded by MVA induces CD4+ responses
The depletion of CD8+ T cells from splenocytes followed
by stimulation with Nef peptides showed that only ani-
mals immunized repeatedly with DNA (group F; DNAnef
followed by DNAnef) developed a clear CD8+ dependent
IFN-γ response (Figure 4c). The responses in other groups
were largely unaffected by the depletion of CD8+ cells,
indicating that the major part of the effector cells were of
CD4+ origin. A single injection of MVAnef (group C; PBS
followed by MVAnef) resulted in a moderate CD4+
response after stimulation with Nef peptides (Figure 4c).
Taken together, these results indicate that MVAnef induces
a long-lived CD4+  T cell memory response, whereas
repeated DNAnef immunization gives a long-lived CD8+
response.
Intracellular cytokine staining of cryo-preserved spleno-
cytes showed that MVAnef induced a potent response in
terms of Nef-specific IFN-γ and TNF-α production by
CD4+ T cells (data not shown). This correlates well with
the findings in the ELISpot assay of the CD4+ responses.
Due to high background and poor viability of the cryop-
reserved CD8 T cells, the intracellular cytokine staining of
these cells gave no further information.
Vaccinia-specific immune responses
The strongest cellular reactivity of splenocytes stimulated
with inactivated vaccinia was observed in animals immu-
nized three times with MVA (groups A and B, Figure 5a).
Analogous to the cellular responses, the strongest vac-
cinia-neutralizing antibody responses were detected in the
animals immunized three times with MVA (groups A and
B, Figure 5b). These animals already had high titers of
neutralizing antibodies two weeks after the two initial
injections (titers of 512 for 50% neutralization of vac-
cinia). These responses persisted for the 39 weeks until the
late boost (Figure 5b). Sera collected after the third injec-
tion from the animals immunized repeatedly with MVA
(groups A and B) could be diluted several thousand times
and still display more than 50% neutralization of vaccinia
in vitro (Figure 5b). Animals immunized only once with
MVA had antibody titers of 256 against vaccinia.
IFN-γ ELISpot secretion by PBMC following stimulation with  peptides covering Nef Figure 3
IFN-γ ELISpot secretion by PBMC following stimulation with 
peptides covering Nef. Results from 3 time-points following 
the two initial immunizations but prior to the boost at week 
44.
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Discussion
The inability of plasmid-based vaccines to induce long-
lasting immune responses in humans has resulted in the
development of alternative strategies for delivering
genetic immunogens. The concept of heterologous prime/
boost immunization, where two or more vaccine modali-
ties are combined, is now rather well established in exper-
imental vaccinology [27,28] and has also been evaluated
in clinical trials [29,30]. One of the most promising
prime/boost strategies is the combination of naked DNA
with viral vectors. Several attenuated and modified
viruses, including species within the families of Pox,
Adeno and Alphaviruses, are being explored both as
stand-alone vaccine vectors and as components of prime
boost vaccine regimens.
We have used two constructs, plasmid DNA and Modified
Vaccina virus Ankara (MVA), for delivering the HIV-1 nef
gene. We assessed the long-term toxicology and immune
responses following immunization with either vector
alone or in a DNA prime MVA boost regimen. Both
DNAnef and MVAnef have previously been shown to
induce novel Nef-specific immune responses in HIV-1-
infected humans [9,10]. During the clinical evaluation of
the MVAnef construct in HIV-1 infected persons, several
parameters were assessed to ensure the safety of the con-
struct. The vaccinees were monitored for standard hema-
tologic and laboratory safety parameters and
immunization with MVAnef was concluded to be safe
[10]. However, the ability of Nef to cause transformation
in certain cell types in vitro [17-20] prompted us to per-
Nef responses as measured by ELISpot Figure 4
Nef responses as measured by ELISpot. (A) IFN-γ and (B) IL-2 secretion by splenocytes stimulated with either a pool of over-
lapping peptides covering Nef or a pool of control peptides (Tick Borne Encephalitis virus, TBE). * indicates a significant differ-
ence (p < 0.05). Error bars show standard deviations of all animals in each group. (C) IFN-γ secretion by pooled splenocytes 
from all animals in each group (black bars) or by pooled splenocytes depleted of CD8 + cells (white bars). M = MVA, D = 
DNA.
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form an even more extensive toxicological evaluation of
the vaccine, using a model permitting histopathological
analysis of the major organs as well as analysis of the
blood and bone marrow for the occurrence of tumors and
other abnormalities. These types of extensive analysis are
difficult to perform in a clinical trial since they require
multiple organ biopsies.
We primed BALB/c mice with two injections of MVAnef or
DNAnef and thirty-nine weeks later the animals received
either a homologous or a heterologous boost. Three
weeks after the boost, the animals were sacrificed and
organs and blood were collected for toxicological as well
as immunological analysis. The toxicological evaluation
led to the conclusion that immunization of the mice with
MVAnef did not cause pathological changes in the investi-
gated organs or in the blood. Some abnormalities were
noted, including accumulation of white blood cells in the
lungs, a moderate decrease of segmented granulocytes in
the blood and a slight to moderate degree of anisocytosis
(abnormal size of the erythrocytes), poikilocytosis (irreg-
ularly shaped erythrocytes) and polychromasia of red
blood cells. These observations were made in both immu-
nized and control animals and were assigned to normal
age-related pathology, not to effects of the vaccination.
The absence of tumors and other adverse effects caused by
the vaccine one year after the immunization is encourag-
ing, since the animals were immunized with a massive
dose of vaccine in relation to their body weight. We there-
fore conclude that immunizing with MVAnef does not
induce any long-term toxicity.
One issue when using MVA as a vehicle for gene delivery
is the anti-vector immunity that inevitably will be induced
after immunization. Anti-vector immunity may neutralize
the viral vector in subsequent vaccinations, possibly lead-
ing to a reduced capacity to boost the immune responses
directed against the antigen expressed by the vector [31].
Strong cellular reactivity as well as high titers of vaccinia
neutralizing antibodies were detected in animals immu-
nized repeatedly with MVA (Figure 5). However, the
immune responses against Nef could clearly be boosted
by a third injection of MVAnef despite potent anti-vector
reactivity (Figure 5b). The ability to boost immune
responses despite the presence of neutralizing antibodies
directed against the viral vector has been observed by oth-
ers [32] and is of importance for clinical vaccine regimens
where multiple MVA injections are given. The matter of
anti-MVA reactivity is also of interest since the virus has
been proposed as a candidate smallpox vaccine and there
are results indicating that MVA is a potent inducer of
immunity to smallpox [33,34]. The immunity to small-
Reactivity against the vaccinia vector Figure 5
Reactivity against the vaccinia vector. A) IFN-γ and IL-2 secretion by splenocytes isolated 3 weeks following the late boost and 
stimulated with inactivated vaccinia. * indicates a significant difference (p < 0.05), M = MVA, D = DNA. Error bars show stand-
ard deviations of all animals in each group. B) End-point serum dilution for a 50% in vitro neutralization of vaccinia virus at the 
time of the late boost (black bars) and at the time of sacrifice, 3 weeks after the late boost (white bars).
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pox induced by the MVA would of course be an additional
beneficial effect of using this particular viral vector for
delivering other vaccine antigens.
The humoral and cellular immune responses against Nef
were monitored during the forty weeks between the sec-
ond and third immunizations. The two initial MVAnef
immunizations induced prominent and stable long-last-
ing humoral responses against Nef. These results demon-
strate the potential of MVA to induce a long-lasting B-cell
memory to the vectored antigen, which is highly desirable
for a vaccine vector. Intriguingly, when the animals
primed with DNAnef were boosted with MVAnef, the
humoral response to Nef increased to levels similar to
those seen in the animals immunized repeatedly with
MVAnef. This increase occurred despite undetectable anti-
body levels following the two priming DNAnef injections,
demonstrating the capacity of plasmid-encoded Nef to
prime humoral immune responses.
Interestingly, no significant difference in Nef-specific cel-
lular responses could be detected when comparing the
animals immunized repeatedly with either MVAnef or
DNAnef or the prime/boost combination of the two vec-
tors. Importantly, as discussed above for the Nef-specific
humoral responses, the nef-specific cellular responses
could also be readily boosted (Figure 4) despite the pres-
ence of anti-vector immunity (Figure 5).
The Nef-specific cellular responses that were detected two
weeks after the second immunization, with either
DNAnef or MVAnef, decreased over time (Figure 3) but
were readily boosted forty weeks later (Figure 4), demon-
strating the induction of a long-lasting cellular Nef-spe-
cific immunological memory. Importantly, a late boost
with DNAnef could significantly enhance immune
responses induced with the same DNA construct. These
results suggest that the same plasmid vaccine can be used
for late boosting and not only, as is common today, for
priming of an immune response. This finding could have
a great impact on upcoming DNA vaccine trials, as there
are several advantages of naked DNA over viral vectors,
including the lack of preexisting immunity to the plasmid
vector DNA.
Ex-vivo depletion of CD8+ cells from splenocytes revealed
that only animals immunized with plasmid DNAnef three
times over one year displayed a prominent CD8+ depend-
ent response. In contrast, animals immunized with
MVAnef primarily developed CD4+ responses to nef, a
finding that was further confirmed by intracellular stain-
ing of cryo-preserved splenocytes. These findings are anal-
ogous to observations in human trials [10]. Interestingly,
animals primed with plasmid DNA and subsequently
boosted with MVA also predominantly exhibited CD4+
and humoral responses, suggesting that MVAnef primarily
induce a CD4+ T cell memory, while repeated DNA immu-
nization instead amplify the CD8 T cell response.
Conclusion
To conclude, this study shows i) that the nef gene vectored
by MVA does not induce malignancies or other adverse
effects in mice and may safely be used as a vaccine in
humans; ii) that a DNAnef prime followed by an MVAnef
boost induced a strong and robust CD4+  T cellular
response balanced with high titers of Nef-specific antibod-
ies; iii) that immunizing repeatedly with DNAnef induced
a strong CD8+  T cellular response, while low or no
humoral or CD4+ T cell responses could be detected; and
iv) that it is possible to boost the Nef-specific responses
using MVAnef despite the presence of neutralizing anti-
vector antibodies.
Our findings have important implications for human
immunizations since we demonstrate the possibility to
induce a long-lasting immune memory, which can be
readily boosted by an additional injection of DNA or
recombinant MVA vaccine. Moreover, we demonstrate
that it is possible to focus the immune response to either
a CD4+ or CD8+ response by selecting the appropriate
boosting vector.
Methods
Immunizations
The immunogens used were the plasmid DNAnef and
MVAnef, both encoding wild type HIV-1LAI Nef. Both
DNAnef and MVAnef have been described elsewhere
[10,35] and shown to induce Nef-specific immune
responses in humans [9,10]. Five-week-old female BALB/
c mice (Charles River, Germany) were immunized at week
0 and week 5 with either 100 μg of DNAnef intramuscu-
larly (10 mice, 50 μg DNA/hind leg, 2 mg DNA/ml
saline), 108 pfu of MVAnef intraperitoneally (15 mice, 109
pfu/ml) or 100 μl saline intraperitoneally. Forty-four
weeks following the initial immunization, each group of
animals was split into two and boosted according to figure
1. Blood was drawn from the animals at weeks 2, 7, 23
and 44. Three weeks after the last injection the animals
were sacrificed and organs and blood were harvested.
Toxicology and histopathology
Animals were anaesthetized with isofluran and sacrificed
by cervical dislocation. A licensed veterinarian performed
necropsy at the time of sacrifice and the subsequent toxi-
cological examination was performed by the GLP accred-
ited laboratory at BioVet AB (Sollentuna, Sweden). The
spleen from each animal was weighed and the following
organs were preserved in 4% neutral buffered formalde-
hyde solution for subsequent examination: lungs, liver,
spleen, inguinal lymph nodes, kidneys, ovaries and boneInfectious Agents and Cancer 2007, 2:14 http://www.infectagentscancer.com/content/2/1/14
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marrow. The listed organs were embedded in Histowax
(Histolab Products AB, Sweden) and, after dehydration,
sectioned at 4–6 μm, stained with hematoxylin and eosin
and subsequently examined microscopically for patholog-
ical changes. Blood smears from each animal were pre-
pared from peripheral blood and air-dried at the time of
necropsy. The smears were fixed in methanol, stained
according to the method of May-Grünewald-Giemsa and
examined microscopically.
ELISA
ELISA plates (Nunc MaxisorpOdense, Denmark) were
coated with recombinant Nef (1.5 μg/ml) overnight at
room temperature. The plates were blocked for 1 hour
with 5% fat-free milk in PBS. Serum from each animal was
diluted in 2.5 % fat-free milk in PBS and added to the
wells. After 12 hours, reactive antibodies were detected
with goat anti-mouse IgG antibodies conjugated to HRP
(DAKO PO449, Denmark) diluted 1/3500 in 1.25 % fat-
free milk. The plates were then developed for 30 min by
adding O-phenylene diamine (Sigma, Sweden). The color
reaction was stopped with 2.5 M H2SO4 and the optical
density (OD) was read at 490 nm. The sera were consid-
ered positive for anti-Nef antibodies if the OD exceeded
the mean value for negative samples (pre-immunization
bleedings) plus 3 standard deviations.
Neutralization of Vaccinia
Sera from animals in each group were pooled and inacti-
vated at 56°C for 30 minutes and subsequently diluted.
Diluted sera and vaccinia virus (Virus strain Elstree, Bern-
abiotech, Switzerland) of a final concentration of 167
pfu/ml were mixed in EMEM (2% FCS, Sigma, Sweden)
and incubated for 90 minutes at 37°C. Virus and serum
mixtures were then added in triplicates to fully confluent
green monkey kidney (GMK) cells placed in 48 well
plates. After incubation for 1 hour at 37°C, the serum and
virus mixture was removed and replaced with 0.5 ml fresh
EMEM (2% FCS). Cells were subsequently placed in 5%
CO2 at 37°C. Forty hours later, the cells were stained and
fixed by addition of 50 μl crystal violet diluted in 12%
paraform aldehyde. Thirty minutes later, medium was
removed and the cells were allowed to air-dry. The
number of plaques formed in each well was counted in a
light microscope. The neutralization capacities of sera
from immunized animals were determined by comparing
neutralizing activities of sera from the non-immunized
animals as well as sera from blood drawn prior to the
immunizations.
ELISpot
The extraction and ficoll-paque (Amersham Biosciences
Europe GmbH, Uppsala, Sweden) purification of spleno-
cytes and PBMC were carried out as previously described
[36]. For the depletion of CD8+ T cells, Dynabeads (Dynal
Biotechtech, Oslo, Norway) were used according to the
manufacturer's instructions. The efficiency of CD8+ cell
depletion was confirmed by flow cytometry. Total and
CD8+ depleted splenocytes (106) were stained for 30 min
at 4°C with FITC conjugated anti CD4 antibodies and
with PerCP conjugated anti-CD8a antibodies (BD
Pharmingen). On average, 97% ± 1.4% of the CD8+ cells
were removed. Splenocytes from individual animals or
pooled splenocytes from all animals in each group, before
and after CD8+ T cell depletion, were suspended in RPMI
1640 (Sigma, Sweden) supplemented with penicillin/
streptomycin (PEST, Invitrogen Corporation, Carlsbad,
CA, USA) and 10% fetal calf serum (FCS, Sigma, Sweden)
and were distributed in anti-Interferon-γ (IFN-γ)
(Mabtech, Nacka, Sweden) antibody coated 96-well poly-
vinylidene fluoride (PVDF) bottomed plates (MAIPN
4510, Millipore Corporation, Bedford, MA, USA). Splen-
ocytes, 2 × 105/well, were stimulated either with 15-mer
peptides (overlapping by 10 aa, 5 μg/peptide/ml) cover-
ing Nef or with heat-inactivated vaccinia (95°C, 30 min)
virus, 5 × 106 pfu/well. As negative controls, a peptide
library consisting of 18 peptides derived from tick-borne
encephalitis virus (5 μg/ml/peptide) or medium alone
was used. Concanavalin A (1 μg/well, Sigma, Sweden) was
used to confirm cell viability. The plates were then devel-
oped as described by the manufacturer and read in an
ELISpot reader (AID, Germany). Results are given as
cytokine-producing spot-forming cells (SFC) per million
plated cells and responding animals were defined as hav-
ing above 50 SFC per million cells and twice the reactivity
of unstimulated cells from the same animal.
Intracellular cytokine staining
Frozen splenocytes from vaccinated mice were thawed
and incubated overnight at 37°C. The next day 12 × 106
cells of each mouse spleen were pooled to obtain repre-
sentative pools for each vaccination group. Splenocytes
were stimulated with either a peptide pool covering the
whole Nef protein by 15-mer peptides (overlapping by 10
aa) or a control peptide at 1 μg/peptide/ml in the presence
of 1 μg/ml Brefeldin A (Sigma) for 5 h. The subsequent
staining of cells was carried out according to previously
described procedures [37]. Briefly, the cells were incu-
bated for 20 min with ethidium monazide (Molecular
Probes) for live/dead discrimination and anti-Mouse-Fc-
Ab (Pharmingen) to avoid unspecific binding of surface
marker antibodies for 20 min and washed three times.
Surface markers were stained with PE conjugated anti-
CD8α, PerCP conjugated anti-CD4 and APC conjugated
anti-CD62L (all Pharmingen) and washed again three
times. Intracellular cytokine staining for IFN-γ and TNF-α
production was performed by using the Cytofix/
Cytoperm kit (Pharmingen) according to the manufac-
turer's recommendations. Data were acquired on a FACS-Infectious Agents and Cancer 2007, 2:14 http://www.infectagentscancer.com/content/2/1/14
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can (Becton Dickinson) and further analyzed with FlowJo
(Tree Star) software.
Statistical analysis
Statistical analyses were performed using the SPSS pro-
gram, version 10.1.0 for Windows. The criterion for statis-
tical significance was p ≤ 0.05. Since most of the data were
not normally distributed, the non-parametric Kruskal-
Wallis test and the Mann-Whitney U test were used. Fol-
lowing a statistically significant Kruskal-Wallis test, the
Mann-Whitney U test was used for pairwise post hoc com-
parison.
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